O'Neill Gilmore Neil 4

What Happened

• Neil O'Neill, CEO and Director of Editas Medicine (EDIT), sold 15,380 shares on June 3, 2026 for a total of approximately $41,543. The filing reports a weighted-average price of $2.70 per share; the sale was recorded as a disposition (code S) and represents shares sold to meet tax withholding obligations following RSU vesting.
• The filing notes the sale was executed under a durable automatic sales instruction plan (adopted April 13, 2022) and was not a discretionary trade by the reporting person.

Key Details

• Transaction date: June 3, 2026; Form 4 filed June 5, 2026 (appears timely).
• Shares sold: 15,380; reported total value: $41,543.
• Price: weighted average $2.70; executed in multiple trades at prices ranging $2.7010–$2.7250 (per footnote).
• Reason/footnote: Sale effected pursuant to an automatic sales instruction to satisfy tax withholding after RSU vesting on June 2, 2026 (Footnote F1). Filing can provide full trade-level prices upon request (Footnote F2).
• Shares owned after the transaction: not specified in the provided filing.

Context

• This was a routine tax-withholding sale tied to restricted stock unit vesting (not a discretionary market-timed sale), which is common for insiders when awards vest. Such transactions typically reflect tax needs rather than a change in the insider’s view of the company.